Powered by

-MDxHealth - Multi-center Study Validates SelectMDx's High Negative Predictive Value and Sensitivity

Jun 11, 2019 - ENP Newswire

IRVINE - MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative molecular diagnostics company, today announced that a second clinical validation study demonstrating the performance of its liquid biopsy test SelectMDx for Prostate Cancer has been published in the The Journal of Urology.

In a clinical study of 1,955 men undergoing initial prostate biopsy, SelectMDx yielded a 95% negative predictive value and 93% sensitivity for the detection of clinically significant prostate cancer...